Key Clinical Formulas & Scores
Dilation (cm): 0=0, 1-2=1, 3-4=2, โฅ5=3
Effacement (%): 0=0-30%=0, 40-50%=1, 60-70%=2, โฅ80%=3
Station: -3=0, -2=1, -1/0=2, +1/+2=3
Consistency: Firm=0, Medium=1, Soft=2
Position: Posterior=0, Midposition=1, Anterior=2
Score: โค5 = unfavorable cervix (need cervical ripening)
Score โฅ6 = favorable (proceed with induction)
Stage I: Confined to cervix (IA=microinvasive, IB=clinically visible)
Stage II: Beyond cervix, not to pelvic wall/lower vagina
Stage III: Extends to pelvic wall, lower 1/3 vagina, hydronephrosis
Stage IV: Mucosa of bladder/rectum or distant metastasis
Treatment: IA1=cone biopsy, IA2=modified radical hysterectomy, IB-IIA=radical hysterectomy + pelvic lymphadenectomy, IIB-IV=definitive chemoradiation
Stage I: Ovaries only (IA=1 ovary, IB=both, IC=surface involvement/ascites)
Stage II: Pelvic extension (IIA=uterus/fallopian tubes, IIB=other pelvic tissue)
Stage III: Peritoneal implants outside pelvis/retroperitoneal nodes
Stage IV: Distant metastasis (pleural effusion, parenchymal liver mets)
Treatment: Surgical staging + debulking, then carboplatin/paclitaxel chemotherapy. Maintenance: bevacizumab, PARP inhibitors (if BRCA/HRD+)
Negative: NILM (Negative for Intraepithelial Lesion or Malignancy)
ASC-US: Atypical Squamous Cells of Undetermined Significance
ASC-H: ASC, cannot exclude HSIL
LSIL: Low-grade Squamous Intraepithelial Lesion (HPV effect/CIN1)
HSIL: High-grade Squamous Intraepithelial Lesion (CIN2/CIN3)
SCC: Squamous Cell Carcinoma
Management: ASC-US โ HPV testing (if +, colposcopy); ASC-H/LSIL/HSIL โ colposcopy with biopsy
HPV 16, 18 (cause ~70% of cervical cancers)
HPV 31, 33, 45, 52, 58 (additional high-risk)
HPV 6, 11 (low-risk, cause genital warts)
Vaccination: 9-valent (6, 11, 16, 18, 31, 33, 45, 52, 58)
Screening: Cytology alone q3y (21-29), Cytology + HPV co-testing q5y (30-65)
USPSTF: Primary HPV testing every 5 years age 30-65 is now acceptable
Core Concepts
Pelvic Inflammatory Disease (PID)
Clinical criteria (CDC): cervical motion tenderness + uterine tenderness + adnexal tenderness (minimum). Additional: fever >38.3ยฐC, mucopurulent cervical discharge, elevated ESR/CRP, NAAT positive for N. gonorrhoeae/C. trachomatis. Treatment: outpatient โ ceftriaxone 500mg IM single dose + doxycycline 100mg BID ร 14 days + metronidazole 500mg BID ร 14 days. Inpatient โ cefotetan/cefoxitin IV + doxycycline IV. Complications: tubo-ovarian abscess, infertility, ectopic pregnancy, chronic pelvic pain.
Abnormal Uterine Bleeding (AUB-COEIN Classification)
Structural: Polyp (AUB-P), Adenomyosis (AUB-A), Leiomyoma (AUB-L), Malignancy (AUB-M). Non-structural: Coagulopathy (AUB-C), Ovulatory dysfunction (AUB-O), Endometrial (AUB-E), Iatrogenic (AUB-I), Not yet classified (AUB-N). PALM-COEIN system guides evaluation. Endometrial biopsy for age โฅ45 or risk factors (obesity, chronic anovulation, tamoxifen, Lynch). TVUS for initial structural evaluation.
Endometriosis
Definition: ectopic endometrial tissue outside the uterus. Theories: retrograde menstruation, coelomic metaplasia, lymphatic/vascular spread, stem cells. Symptoms: dysmenorrhea, dyspareunia, dyschezia, dysuria, chronic pelvic pain, infertility. Staging: rASRM (minimal I to severe IV). Gold standard for diagnosis: laparoscopy with biopsy. Treatment: NSAIDs, combined OCPs, progestins (norethindrone, dienogest), GnRH agonists (leuprolide) with add-back, aromatase inhibitors. Surgical: excision/ablation, hysterectomy + BSO for refractory.
Preeclampsia & Hypertensive Disorders of Pregnancy
Diagnostic criteria: BP โฅ140/90 after 20 weeks + proteinuria (โฅ300 mg/24h or protein/creatinine โฅ0.3) OR BP โฅ140/90 + end-organ dysfunction (thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, cerebral/visual symptoms). Severe features: BP โฅ160/110, HELLP syndrome, eclampsia. Treatment: delivery is definitive. MgSOโ for seizure prophylaxis (4-6g load + 1-2g/hr maintenance). Antihypertensives: labetalol, nifedipine, hydralazine (target BP <160/110).
Clinical Case Studies
Case 1: Post-Coital Bleeding & Cervical Cancer
Patient: 38-year-old G2P2, presents with post-coital bleeding ร 3 months. Pap smear: HSIL. HPV positive type 16. Colposcopy: aceto-white lesion at transformation zone with punctation. Biopsy: squamous cell carcinoma, moderate differentiation.
Diagnosis: Stage IB1 cervical cancer (lesion 2.5 cm, confined to cervix on MRI).
Management: Radical hysterectomy (type B/C1) + pelvic lymphadenectomy + sentinel lymph node mapping. Pathology: negative nodes, clear margins โ observation. If positive nodes or positive margins โ adjuvant concurrent chemoradiation (cisplatin 40 mg/kg weekly ร 6 cycles with external beam RT ยฑ brachytherapy).
Case 2: Ectopic Pregnancy
Patient: 29-year-old G1P0, 7 weeks amenorrhea by dates, sharp right lower quadrant pain with vaginal spotting. ฮฒ-hCG = 3,500 mIU/mL. Transvaginal US: empty uterus, right adnexal gestational sac with fetal pole.
Diagnosis: Right tubal ectopic pregnancy.
Management: Unruptured, hemodynamically stable, ฮฒ-hCG <5,000 โ medical management with methotrexate (single dose 50 mg/mยฒ IM or multi-dose regimen). Alternative: salpingostomy via laparoscopy. Follow ฮฒ-hCG until negative. Contraindications to methotrexate: rupture, hemodynamic instability, breastfeeding, immunodeficiency, alcoholism, liver/renal disease, blood dyscrasias.
Case 3: Abnormal Uterine Bleeding
Patient: 47-year-old G3P3, heavy menstrual bleeding ร 8 months with clots, fatigue. Hgb 8.2 g/dL. TVUS: endometrial thickness 14 mm, heterogeneous. No focal lesions.
Assessment: Endometrial biopsy: complex atypical hyperplasia (precancerous, ~30-40% risk of concurrent carcinoma).
Management: Progestin therapy (medroxyprogesterone acetate 10-20 mg daily or LNG-IUD) for patients desiring fertility preservation with close surveillance. Total hysterectomy with BSO recommended for definitive treatment in patients who have completed childbearing. If invasive carcinoma found โ staging surgery (hysterectomy, BSO, pelvic/para-aortic lymphadenectomy, omentectomy, peritoneal washings).
Practice Questions
A: Score โค5 = unfavorable cervix. Use cervical ripening with prostaglandins (dinoprostone/misoprostol) or mechanical methods (Foley balloon) before oxytocin induction.
A: HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. This covers the two most oncogenic types (16, 18) causing ~70% of cervical cancers plus 5 additional high-risk types.
A: Delivery is the only definitive treatment. Favorable Bishop (โฅ6) โ proceed with induction of labor (oxytocin + amniotomy if needed) after maternal stabilization with MgSOโ and antihypertensives. Expedite delivery if maternal/fetal deterioration.
A: Laparoscopy with histological biopsy. Transvaginal ultrasound is useful for endometriomas and deep infiltrating disease but cannot rule out superficial peritoneal disease.
A: Return to routine screening โ repeat cytology and HPV co-testing in 3 years (or cytology alone in 1 year). ASC-US with negative high-risk HPV has a very low risk of CIN2+.